Short Interest in ImmunoGen, Inc. (NASDAQ:IMGN) Decreases By 13.9%
Short Interest in ImmunoGen, Inc. (NASDAQ:IMGN) Decreases By 13.9%
ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totalling 12,310,000 shares, a decline of 13.9% from the August 15th total of 14,300,000 shares. Based on an average daily trading volume, of 3,140,000 shares, the short-interest ratio is presently 3.9 days.
免疫遗传公司(纳斯达克：IMGN-GET评级)是8月份空头股数价格大幅下降的接受者。截至8月31日，空头股数共有12,310,000股，较8月15日的14,300,000股减少13.9%。以日均成交量314万股计算，目前短息比为3.9天。
ImmunoGen Stock Performance
ImmunoGen股票表现
Shares of NASDAQ:IMGN traded down $0.34 on Friday, hitting $5.04. The stock had a trading volume of 8,902,983 shares, compared to its average volume of 2,536,643. ImmunoGen has a twelve month low of $3.10 and a twelve month high of $7.77. The firm's 50 day moving average price is $5.40 and its 200-day moving average price is $4.83. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -7.30 and a beta of 0.90.
上周五，新浪纳斯达克股价下跌0.34美元，至5.04美元。该股成交量为8,902,983股，而平均成交量为2,536,643股。ImmunoGen的12个月低点为3.10美元，12个月高点为7.77美元。该公司的50日移动均线价格为5.40美元，200日移动均线价格为4.83美元。该公司市值为11.1亿美元，市盈率为-7.30倍，贝塔系数为0.90。
ImmunoGen (NASDAQ:IMGN – Get Rating) last issued its earnings results on Friday, July 29th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.03). ImmunoGen had a negative net margin of 179.64% and a negative return on equity of 67.02%. The firm had revenue of $14.20 million during the quarter, compared to analyst estimates of $16.18 million. During the same quarter in the prior year, the firm posted ($0.15) EPS. The firm's revenue for the quarter was down 16.0% on a year-over-year basis. As a group, sell-side analysts predict that ImmunoGen will post -0.89 EPS for the current year.
免疫基因(纳斯达克：IMGN-GET评级)上一次发布收益报告是在7月29日(星期五)。这家生物技术公司公布了该季度每股收益(0.24美元)，低于普遍预期的(0.21美元)和(0.03美元)。免疫基因公司的净利润率为负179.64%，净资产回报率为负67.02%。该公司本季度营收为1,420万美元，而分析师预期为1,618万美元。在去年同期，该公司公布了每股收益(0.15美元)。该公司本季度营收同比下降16.0%。卖方分析师预测，作为一个整体，免疫系统本年度的每股收益将达到0.89欧元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Institutional Investors Weigh In On ImmunoGen
机构投资者对免疫基因的看法
Several institutional investors and hedge funds have recently made changes to their positions in IMGN. RA Capital Management L.P. raised its holdings in shares of ImmunoGen by 7.4% in the first quarter. RA Capital Management L.P. now owns 21,741,458 shares of the biotechnology company's stock valued at $103,489,000 after buying an additional 1,500,000 shares during the last quarter. State Street Corp raised its holdings in shares of ImmunoGen by 32.8% in the second quarter. State Street Corp now owns 18,199,554 shares of the biotechnology company's stock valued at $81,898,000 after buying an additional 4,492,165 shares during the last quarter. BlackRock Inc. raised its holdings in shares of ImmunoGen by 10.6% in the first quarter. BlackRock Inc. now owns 16,432,933 shares of the biotechnology company's stock valued at $78,225,000 after buying an additional 1,569,629 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of ImmunoGen by 2.3% in the first quarter. Vanguard Group Inc. now owns 15,478,516 shares of the biotechnology company's stock valued at $73,678,000 after buying an additional 346,764 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C raised its holdings in shares of ImmunoGen by 332.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 15,020,490 shares of the biotechnology company's stock valued at $67,592,000 after buying an additional 11,549,815 shares during the last quarter. Institutional investors and hedge funds own 95.58% of the company's stock.
几家机构投资者和对冲基金最近改变了他们在IMGN的头寸。RA Capital Management L.P.在第一季度增持了免疫遗传股份7.4%。Ra Capital Management L.P.现在拥有这家生物技术公司21,741,458股股票，价值103,489,000美元，上个季度又购买了1,500,000股。道富银行第二季度增持了32.8%的ImmunoGen股票。道富集团现在拥有18,199,554股生物技术公司的股票，价值81,898,000美元，在上个季度又购买了4,492,165股。贝莱德股份有限公司在第一季度增持了免疫遗传的股票10.6%。贝莱德股份有限公司现在持有这家生物技术公司16,432,933股股票，价值78,225,000美元，在上个季度又购买了1,569,629股。先锋集团(Vanguard Group Inc.)第一季度增持了2.3%的ImmunoGen股票。先锋集团(Vanguard Group Inc.)目前持有这家生物技术公司15,478,516股股票，价值73,678,000美元，上一季度又购买了346,764股。最后，Deerfield Management Company L.P.Series C在第二季度增持了332.8%的免疫基因股票。Deerfield Management Company L.P.C系列现在拥有这家生物技术公司的15,020,490股股票，价值67,592,000美元，上个季度又购买了11,549,815股。机构投资者和对冲基金持有该公司95.58%的股票。
About ImmunoGen
关于免疫基因
(Get Rating)
(获取评级)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
免疫基因公司是一家临床阶段的生物技术公司，开发抗体-药物结合(ADC)疗法来治疗癌症。该公司的候选产品包括针对叶酸受体α(FRA)的ADC Mirvetuximab soravtansine，它正处于治疗对铂耐药的卵巢癌的第三阶段临床试验；以及Pivekimab Sunirine，一种针对CD123的ADC，正处于治疗急性髓系白血病和原始浆细胞样树突状细胞肿瘤的第二阶段临床试验。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- 免费获取StockNews.com关于免疫基因的研究报告(IMGN)
- 第四季度值得考虑的3家银行
- 股市：红海中的三座强国
- 有什么办法可以治愈Teladoc股票的问题吗？
- 没有人告诉这三只股票这是下跌的一周
- MarketBeat：回顾一周9/12-9/16
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫基因日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对免疫系统及相关公司评级的每日简明摘要。